Aegle Therapeutics is a first in class, phase 1/2a stage biotechnology company isolating extracellular vesicles including exosomes (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (DEB), a rare genetic pediatric connective tissue disorder. Aegles EV therapy, using its proprietary platform isolation technology, is cell-free and has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegles EVs deliver COL7, COL7A1 mRNA and the regenerative signals of MSCs to diseased cells and present a unique, multifaceted approach to DEB. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can accelerate and enhance healing, reduce scarring, minimize contraction and improve overall cosmesis.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Nationally (across the country)
Aegle’s IND for DEB was cleared by the FDA in April of 2019 and the Company expects to enter the clinic in 1Q 2021. Aegle’s platform technology, based on intellectual property exclusively licensed from the University of Miami and developed by Chief Scientific Officer, Evangelos Badiavas, M.D., Ph.D., has a broad range of potential indications including severe dermatological conditions. Aegle has locations in Miami, FL and Arlington, MA.